Incidence of adverse events among healthcare workers following H1N1 mass immunization in Ghana: A prospective study

Drug Safety

Volumn 36, Issue 4, 2013, Pages 259-266

  Ankrah, Daniel N A ^a,b   Mantel Teeuwisse, Aukje K ^b   De Bruin, Marie L ^b   Amoo, Philip K ^a   Ofei Palm, Charles N ^a   Agyepong, Irene ^c   Leufkens, Hubert G M ^b  

^a KORLE BU TEACHING HOSPITAL   (Ghana)

^b UTRECHT UNIVERSITY   (Netherlands)

^c Ghana Statistical Service   (Ghana)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ADULT; APPETITE; ARTHRALGIA; ARTICLE; BEHAVIOR; CHILL; DELTOID MUSCLE; DIZZINESS; DRUG FEVER; DRUG INDUCED HEADACHE; DYSPHONIA; EYE PAIN; FEMALE; FOLLOW UP; GHANA; HEALTH CARE PERSONNEL; HOSPITALIZATION; HUMAN; INFLUENZA A (H1N1); INJECTION SITE PAIN; LOWEST INCOME GROUP; LYMPHADENOPATHY; MALE; MASS IMMUNIZATION; MEDICAL INFORMATION; MYALGIA; PALLOR; PRIORITY JOURNAL; RHINORRHEA; SIDE EFFECT; SNEEZING; SOMNOLENCE; SORE THROAT; TACHYCARDIA; TINNITUS; WEAKNESS;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; FEMALE; GHANA; HEALTH PERSONNEL; HUMANS; INCIDENCE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MASS VACCINATION; PROSPECTIVE STUDIES; VACCINATION;

EID: 84876698174     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-013-0037-7     Document Type: Article

References (48)

1. WHO. A practical handbook on the pharmacovigilance of malaria medicines. http://www.who.int/malaria/publications/atoz/malaria-pharmavigil.pdf. Accessed 6 Mar 2013.
2. WHO, Health Technology and Pharmaceuticals, Medicines Policy and Standards. Pharmacovigilance for antiretrovirals in resource-poor countries. http://www.who.int/medicines/publications/PhV-for-antiretrovirals.pdf. Accessed 6 Mar 2013.
3. Doll R, Hill AB. Smoking and carcinoma of the lung, preliminary report. BMJ. 1950;(ii):739-48.
4. Stampfer MJ, Willet WC, Colditz GA, et al. A prospective study of post-menopausal estrogen therapy and coronary heart disease. N Engl J Med. 1985;313:1044-9.
5. Ascherio A, Rim EB, Stampfer MJ, et al. Dietary intake of marine n-3 fatty acids, fish intake, and the risk of coronary disease among men. N Engl J Med. 1995;332:977-82.
6. Szklo M, Nieto FJ. Epidemiology beyond the basics. 2nd ed. Sudbury: Jones and Bartlett Publishers; 2007.
7. Update on current situation: pandemic influenza H1N1 in Ghana as at 12/08/2010. Accra: Ghana Health Service, 2010.
8. Nolan T, McVernon J, Skeljo M, Richmond P, Wadia U, Lambert S, et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in infants and children: a randomized trial. JAMA. 2010;303:37-46.
9. WHO. Weekly epidemiological record: Strategic Advisory Group of Experts on Immunization - report of the extraordinary meeting on the influenza A (H1N1) 2009 pandemic, 7 July 2009. http://www.who.int/wer/2009/wer8430.pdf. Accessed 21 Nov 2010.
10. Ministry of Health, Ghana. H1N1 vaccine deployment plan. Accra: Ministry of Health, 2010.
11. Vellozzi C, Broder KR, Haber P, Guh A, Nguyen N, et al. Adverse events following influenza A(H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010. Vaccine. 2010;28:7248-55.
12. Jacquet A, Robine I, Durrieu G, Auriche P, Bidault I, Ouaret S, et al. Intensive pharmacovigilance monitoring for influenza vaccines and antiviral drugs used during the influenza A(H1N1)v pandemic: the French experience. Drug Safety. 2010;33(10):909-10.
13. van Puijenbroek EP, Broos N, van Grootheest K. Monitoring adverse events of the vaccination campaign against influenza A(H1N1) in the Netherlands. Drug Saf. 2010;33(12):1097-108.
14. Ghana: historical demographic data of the whole country. http://www.populstat.info/Africa/ghanac.htm. Accessed 4 Jul 2011.
15. ® suspension and emulsion for emulsion for injection: summary of product characteristics. Last updated on the eMC 23/09/2010. http://www.medicines.org.uk/EMC/medicine/22352/SPC/ Pandemrix+suspension+and+emulsion+for+emulsion+for+injection/. Accessed 21 Nov 2010.
16. Ho T, Wang S, Lui C. Historical review of pandemic influenza A in Taiwan, 2009. Paediatr Neonatol. 2009;51(2):83-8.
17. North Yorkshire Health Protection Unit and North Yorkshire and York NHS Primary Care Trust. Vaccine incident reporting form. http://www.nyypct.nhs.uk/ ClinicalCommunity/docs/PGD-VI/Vaccine%20Incident%20Report%20Form%20v2.pdf. Accessed 4 Jun 2010.
18. Beltuna JP. Legal basis - United States. In: Mann R, Andrews E, editors. Pharmacovigilance. 2nd ed. Chichester: Wiley; 2007. p. 25-34.
19. Public Health Agency of Canada. User guide: report of adverse events following immunization (AEFI). http://www.healthunit.org/professionals/ Influenza/Resources/AEFI%20Form%20User%20Guide.pdf. Accessed 4 May 2012.
20. ® patient information. Available from URL: http://www.guysandstthomasbrc.nihr.ac.uk/Resources/Infectionandimmunity/ PDFpandemrixpatientinformationsheet.pdf. Accessed 6 Mar 2013.
21. Ghana Statistical Service, Ghana Health Service and ICF Macro. Ghana demography and health survey 2008. Accra: Ghana Statistical Service, Ghana Health Service and ICF Macro, 2009.
22. Liang X, Li L, Lui D, Li K, Wu W, Zhu B, et al. Safety of influenza A(H1N1) vaccine in post-marketing surveillance in China. N Engl J Med. 2011;364(7):638-47.
23. Kung H, Huang K, Kao T, Lee Y, Chang F, et al. A clinical study to assess the immunogenicity and safety of a monovalent 2009 influenza A (H1N1) vaccine in an area with low-level epidemics of pandemic influenza. Vaccine. 2010;28:7337-43.
24. Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, et al. Response to a monovalent 2009 influenza A(H1N1) vaccine. New Engl J Med. 2009;365(25):2405-13.
25. Vajo Z, Tamas F, Sinka L, Jankovics I. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomized controlled trial. Lancet. 2010;375:49-55.
26. Plennevaux E, Sheldon E, Blatter M, Reeves-Hoché MK, Denis M. Immune response after a single vaccine against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet. 2010;375:41-8.
27. Roman F, Vaman T, Kafeja F, Hanon E, Damme PV. ASO3A-adjuvanted influenza A(H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis. 2010;51(6):668-77.
28. Liang X, Wang H, Wang J, Fang H, Wu J, et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double blind, randomised, placebo-controlled trial. Lancet. 2010;375:56-66.
29. Iskander JK, Gidudu J, Arboleda N, Huang W. Selected major issues in vaccine safety. Ann Nestlé [Engl]. 2008;66:93-103.
30. Kohl KS, Gidudu J, Bonhoeffer J, et al. The development of standardized case definitions for adverse events following immunization. Vaccine. 2007;25:5671-4.
31. Kohl KS, Bonhoeffer J, Braun MM, et al. The Brighton Collaboration: creating a global standard for case definitions (and guidelines) for adverse events following immunization. In: Henriksen K, Battles JB, Marks ES, Lewin DI, editors. Advances in patient safety: from research to implementation (volume 2, concepts and methodology). Rockville: Agency for Healthcare Research and Quality; 2005. p. 87-102.
32. Bonhoeffer J, Kohl KS, Chen RT, et al. The Brighton Collaboration: enhancing vaccine safety. Vaccine. 2004;22:2046.
33. Bonhoeffer J, Heininger U, Kohl KS, et al. Standardized case definitions of adverse events following immunizations (AEFI). Vaccine. 2004;22:547-50.
34. Kohl KS, Bonhoeffer J, Chen RT, et al. The Brighton Collaboration: enhancing comparability of vaccine safety data. ISPE commentary. Pharmacoepidemiol Drug Saf. 2003;12:335-40.
35. Bonhoeffer J, Kohl KS, Chen RT, et al. The Brighton Collaboration: addressing the need for standardized case definition of adverse events following immunization (AEFI). Vaccine. 2002;21:298-302.
36. Black S, Eskola J, Siegrist C, Halsey N, MacDonald N, et al. Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet. 2009;374:2115-22.
37. Wang Y, Xiao Z, Wang W. Awareness of the background rates of sudden cardiac death during mass immunization with pandemic H1N1 influenza vaccines increases the intended vaccination rate. Prev Med. 2010;51:445-6.
38. Dauvilliers Y, Montplaisir J, Cochen V, Desautels A, Einen M, et al. Post-H1N1 narcolepsy-cataplexy. Sleep. 2010;33(11):1428-30.
39. Caplan AL. Duty to warn? The ethics of disclosing information about possible risks associated with H1N1 vaccination. Sleep. 2010;33(11):1426-7.
40. Zarocosters J. WHO backs further probes into possible link between H1N1 vaccine and narcolepsy in children. BMJ. 2011;342:d909.
41. Geoff W. New findings on H1N1 vaccine prompt revised prescribing advice (news). BMJ. 2011;342:d2524.
42. ®, (H1N1)v influenza and reported cases of narcolepsy (letter). Vaccine. 2011;29(11):2010.
43. WHO. Statement on narcolepsy and Pandemrix. http://www.who.int/vaccine- safety/topic/influenza/pandemrix/h1n1-safety-assessing/narcolepsy-statement- Jul2011/en/. Accessed 10 Mar 2012.
44. European Medicines Agency. European Medicines Agency recommends restricting use of Pandemrix. http://www.ema.europa.eu/docs/en-GB/document- library/Press-release/2011/07/WC500109182.pdf. Accessed 10 Mar 2011.
45. Varricchio F, Iskander J, DeStefano F, Ball R, Pless R, et al. Understanding vaccine safety information from the vaccine adverse reporting system. Pediatr Infect Dis J. 2004;23(4):287-94.
46. Ellenberg SS, Chen RT. The complicated task of monitoring vaccine safety. Public Health Rep. 1997;112(1):10-20.
47. Centers for Disease Control and Prevention. Surveillance for safety after immunization: vaccine adverse events reporting system (VAERS) - United States, 1991-2001. MMWR Surveil Summ. 2003;52:1-24.
48. Broos N, van Puijenbroek EP, van Grootheest K. Fever following immunization with influenza A(H1N1) vaccine in children: a survey based study in the Netherlands. Drug Saf. 2010;33(12):1109-15.